Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655130 in acute generalized pustular psoriasis flare
2017-004231-37Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in generalized pustular psoriasis (GPP) comparing BI 655130 with Placebo (2 arms). Primary endpoint: Generalized Pustular Psoriasis Physician Global Assessment response at Week 1. Started Nov 2018; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on 2017-004231-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004231-37.